PHARMALA BIOTECH HLDG INC (MDXXF)
MDXXF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How MDXXF actually reacts to news — the realized, point-in-time move the market made, measured across 65 labeled events over the last three years with zero look-ahead.
MDXXF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 10% | 42 |
| 30-min | 0.00% | 14% | 42 |
| 60-min | 0.00% | 23% | 44 |
| to close | 0.00% | 40% | 45 |
| Middle 50% of MDXXF reactions | -3.04% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 65 |
Half of all PHARMALA BIOTECH HLDG INC news events land between -3.04% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MDXXF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MDXXF's baseline. Nothing else.
Recent MDXXF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand | Press release | GlobeNewswire | -0.07% | -3.80% | |
| PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill | Press release | GlobeNewswire | +0.00% | +6.75% | |
| PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner | Press release | GlobeNewswire | +0.06% | +9.52% | |
| PharmAla Issues Q3 Financial Statements and AGM Update | Press release | GlobeNewswire | +0.00% | -3.45% | |
| PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset | Press release | GlobeNewswire | — | — | |
| PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 | Press release | GlobeNewswire | +0.00% | -0.57% | |
| PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01 | Press release | GlobeNewswire | +0.00% | -16.82% | |
| PharmAla Issues Q2 Financial Statements and Grants Options | Press release | GlobeNewswire | +1.03% | +2.18% | |
| PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order | Press release | GlobeNewswire | -5.25% | +13.25% | |
| Cortexa Advances Commercialisation of MDMA Supply in Australia | Press release | GlobeNewswire | — | — | |
| PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders | Press release | GlobeNewswire | — | — | |
| PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data | Press release | GlobeNewswire | — | — | |
| PharmAla Announces Changes to Board of Directors | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research | Press release | GlobeNewswire | +0.00% | +11.13% | |
| PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements | Press release | GlobeNewswire | — | — | |
| PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance | Press release | GlobeNewswire | — | — | |
| PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules | Press release | GlobeNewswire | +0.00% | +12.81% | |
| PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital | Press release | GlobeNewswire | +0.00% | +0.32% | |
| PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists | Press release | GlobeNewswire | — | — | |
| PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins | Press release | GlobeNewswire | — | — | |
| PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand | Press release | GlobeNewswire | — | — | |
| PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus | Press release | GlobeNewswire | +0.00% | -6.25% | |
| PharmAla Completes Import of LaNeo MDMA for US Distribution | Press release | GlobeNewswire | — | — | |
| PharmAla Incorporates Australian Entity for Clinical Research | Press release | GlobeNewswire | — | — | |
| PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License | Press release | GlobeNewswire | +0.00% | +0.28% | |
| PharmAla Issues Q3 Financial Statements | Press release | GlobeNewswire | +0.00% | +9.01% | |
| PharmAla Files Preliminary Base Shelf Prospectus | Press release | GlobeNewswire | — | +0.00% | |
| PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update | Press release | GlobeNewswire | -3.30% | -3.30% | |
| PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla | Press release | GlobeNewswire | +0.00% | -2.76% | |
| PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines | Press release | GlobeNewswire | — | — | |
| PharmAla Issues Q2 Financial Statements | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla Contracts with Partner to Act as US Distributor | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington | Press release | GlobeNewswire | +0.00% | -4.79% | |
| PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands | Press release | GlobeNewswire | -3.01% | +5.26% | |
| PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA | Press release | GlobeNewswire | — | +0.00% | |
| PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla Issues Q1 Financial Statements | Press release | GlobeNewswire | — | — | |
| PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement | Press release | GlobeNewswire | — | — | |
| PharmAla Announces Private Placement | Press release | GlobeNewswire | -11.67% | +5.56% | |
| PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License | Press release | GlobeNewswire | +0.00% | -5.42% | |
| PharmAla to supply LaNeo MDMA for Clinical Trial at Yale | Press release | GlobeNewswire | -4.52% | +11.79% | |
| PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA | Press release | GlobeNewswire | +6.06% | +1.67% | |
| PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA | Press release | GlobeNewswire | +1.89% | +5.51% | |
| PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA | Press release | GlobeNewswire | — | — | |
| PharmAla to supply Johns Hopkins Medicine for Clinical Trial | Press release | GlobeNewswire | +0.00% | +16.61% | |
| PharmAla Launches MDMA Clinical Trial Tool for Researchers | Press release | GlobeNewswire | — | — | |
| PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002 | Press release | GlobeNewswire | -24.29% | +9.26% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MDXXF section they belong to.
Where else MDXXF is measured.
MDXXF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PHARMALA BIOTECH HLDG INC's median reaction calculated?
Every labeled MDXXF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 65 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 14% of MDXXF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MDXXF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.